These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 10893592

  • 1. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection.
    Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ.
    J Urol; 2000 Aug; 164(2):388-92. PubMed ID: 10893592
    [Abstract] [Full Text] [Related]

  • 2. Impact of transrectal ultrasound guided prostate biopsy on quality of life: a prospective randomized trial comparing 6 versus 12 cores.
    Naughton CK, Miller DC, Yan Y.
    J Urol; 2001 Jan; 165(1):100-3. PubMed ID: 11125374
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increasing prostate biopsy cores based on volume vs the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity.
    Mariappan P, Chong WL, Sundram M, Mohamed SR.
    BJU Int; 2004 Aug; 94(3):307-10. PubMed ID: 15291857
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection.
    Eskicorapci SY, Guliyev F, Akdogan B, Dogan HS, Ergen A, Ozen H.
    J Urol; 2005 May; 173(5):1536-40. PubMed ID: 15821481
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY.
    Urol Int; 2009 May; 82(3):270-5. PubMed ID: 19440012
    [Abstract] [Full Text] [Related]

  • 8. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
    Stewart CS, Leibovich BC, Weaver AL, Lieber MM.
    J Urol; 2001 Jul; 166(1):86-91; discussion 91-2. PubMed ID: 11435830
    [Abstract] [Full Text] [Related]

  • 9. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR.
    Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
    [Abstract] [Full Text] [Related]

  • 10. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R.
    J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
    [Abstract] [Full Text] [Related]

  • 11. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
    Djavan B, Mazal P, Zlotta A, Wammack R, Ravery V, Remzi M, Susani M, Borkowski A, Hruby S, Boccon-Gibod L, Schulman CC, Marberger M.
    Prostate; 2001 May 01; 47(2):111-7. PubMed ID: 11340633
    [Abstract] [Full Text] [Related]

  • 12. Significance of lateral biopsy specimens during transrectal ultrasound-guided prostate biopsies in Japanese men.
    Shigemura K, Arakawa S, Yamanaka K, Kataoka N, Yuien K, Fujisawa M.
    Int J Urol; 2007 Oct 01; 14(10):935-8. PubMed ID: 17880293
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients.
    Guichard G, Larré S, Gallina A, Lazar A, Faucon H, Chemama S, Allory Y, Patard JJ, Vordos D, Hoznek A, Yiou R, Salomon L, Abbou CC, de la Taille A.
    Eur Urol; 2007 Aug 01; 52(2):430-5. PubMed ID: 17412489
    [Abstract] [Full Text] [Related]

  • 15. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ, van der Cruijsen IW, Schröder FH.
    Urology; 2004 May 01; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [Abstract] [Full Text] [Related]

  • 16. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
    Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M.
    J Urol; 2001 Nov 01; 166(5):1679-83. PubMed ID: 11586201
    [Abstract] [Full Text] [Related]

  • 17. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
    Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T, Naya Y, Ichikawa T.
    Urology; 2006 Oct 01; 68(4):815-9. PubMed ID: 17070359
    [Abstract] [Full Text] [Related]

  • 18. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb 01; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 19. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
    Pelzer A, Bektic J, Berger AP, Pallwein L, Halpern EJ, Horninger W, Bartsch G, Frauscher F.
    J Urol; 2005 Jun 01; 173(6):1926-9. PubMed ID: 15879783
    [Abstract] [Full Text] [Related]

  • 20. Transrectal ultrasound-guided 10-core biopsy of the prostate for Japanese patients.
    Matsubara A, Mutaguchi K, Yasumoto H, Takeshima Y, Teishima J, Seki M, Hasegawa Y, Usui T.
    Hiroshima J Med Sci; 2006 Jun 01; 55(2):65-70. PubMed ID: 16813071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.